Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model

Journal of Immunology

Volumn 179, Issue 2, 2007, Pages 1362-1368

  Kosterink, Jos G W ^a   McLaughlin, Pamela M J ^a   Lub de Hooge, Marjolijn N ^a   Hendrikse, Harry H ^a   Van Zanten, Jacoba ^a   Van Garderen, Evert ^b   Harmsen, Martin C ^a   De Leij, Lou F M H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GD ANIMAL HEALTH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; MONOCLONAL ANTIBODY; UBS 54; UNCLASSIFIED DRUG; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG UPTAKE; EPITHELIUM CELL; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TISSUE DISTRIBUTION;

EID: 34548790820     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.2.1362     Document Type: Article

References (31)

1. Herlyn, M., Z. Steplewski, D. Herlyn, and H. Koprowski. 1979. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 76: 1438-1452.
2. Baeurle, P. A., and O. Gires. 2007. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 96: 417-423.
3. Balzar, M., M. J. Winter, C. J. de Boer, and S. V. Litvinov. 1999. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 77: 699-712.
4. Went, P., M. Vasei, L. Bubendorf, L. Terracciano, L. Tornillo, U. Riede, J. Kononen, R. Simon, G. Sauter, and P. A. Baeuerle. 2006. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br. J. Cancer 94: 128-135.
5. Spizzo, G., P. Went, S. Dirnhofer, P. Obrist, H. Moch, P. A. Baeuerle, E. Mueller-Holzner, C. Marth, G. Gastl, and A. G. Zeimet. 2006. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol. Oncol. 103: 483-488.
6. Kosterink, J. G., M. W. de Jonge, E. F. Smit, D. A. Piers, R. A. Kengen, P. E. Postmus, D, Shochat, H. J. Groen, H. T. The, and L.F. de Leij. 1995. Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC31 in small-cell lung carcinoma. J. Nucl. Med. 36: 2356-2362.
7. Riethmuller, G., E. Holz, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, I. Funke, H. Pichlmaier, H. Hirche, et al. 1998. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven year outcome of a multicenter randomized trial. J. Clin. Oncol. 16: 1788-1794.
8. Punt, C. J., A. Nagy, J. Y. Douillard, A. Figer, T. Skovsgaard, J. Monson, C. Barone, G. Fountzilas, H. Riess, E. Moylan, et al. 2002. Edrocolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 360: 671-677.
9. Liljefors, M., B. Nilsson, J. Fagerberg, P. Ragnhammar, H. Mellstedt, and J. E. Frodin. 2005. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int. J. Oncol. 26: 1581-1589.
10. Oberneder, R., D. Weckermann, B. Ebner, C. Quadt, P. Kirchinger, T. Raum, M. Locher, N. Prang, P. A. Baeuerle, and E. Leo. 2006. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur. J. Cancer 42: 2530-2538.
11. Ammons, W. S., R. J. Bauer, A. H. Horwitz, Z. J. Chen, E. Bautista, H. H. Ruan, M. Abramova, K. R. Scott, and R. L. Dedrick. 2003. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 5: 146-154.
12. de Bono, J. S., A. W. Tolcher, A. Forero, G. F. Vanhove, C. Takimoto, R. J. Bauer, L. A. Hammond, A. Patnaik, M. L. White, S. Shen, et al. 2004. ING-1, a monoclonal antibody targeting EpCAM in patients with advanced adenocarcinomas. Clin. Cancer Res. 10: 7555-7565.
13. Zaloudik, J., S. Basak, M. Nesbit, D. W. Speicher, W. H. Wunner, E. Miller, C. Ernst-Grotkowski, R. Kennedy, L. P. Bergsagel, T. Koido, and D. Herlyn. 1997. Expression of an antigen homologous to the human CO17-1A/GA733 colon cancer antigen in animal tissues. Br. J. Cancer 76: 909-916.
14. Borkowski, T. A., A. J. Nelson, A. G. Farr, and M. C. Udey. 1996. Expression of gp40, the murine homologue of human epithelial cell adhesion molecule (Ep-CAM), by murine dendritic cells. Eur. J. Immunol. 26: 110-114.
15. McLaughlin, P. M., B.-J. Kroesen, W. H. Dokter, H. van der Molen, M. de Groot, M. G. Brinker, K. Kok, M. H. Ruiters, C. H. Buys, and L. F. de Leij. 1999. An EGP-2/Ep-CAM expressing transgenic rat model to evaluate antibody mediated immunotherapy. Cancer Immunol. Immunother. 48: 303-311.
16. McLaughlin, P. M., M. C. Harmsen, W. H. Dokter, B.-J. Kroesen, H. van der Molen, M. G. Brinker, H. Hollema, M. H. Ruiters, C. H. Buys, and L. F. de Leij. 2001. The epithelial glycoprotein 2 (EGP-2) promoter driven epithelial specific expression of EGP-2 in transgenic mice: a model to study carcinoma-directed immunotherapy. Cancer Res. 61: 4105-4111.
17. Dohlsten, M., J. Hansson, L. Ohlsson, M. Litton, and T. Kalland. 1995. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc. Natl. Acad. Sci. USA 92: 9791-9795.
18. Kosterink, J. G., W. Helfrich, and R. F. de Reij. 2001. Strategies for specific drug targeting to tumor cells. In Drug Targeting Organ Specific Strategies. G. Molema and D. K. F. Meijer, eds. Wiley, Weinheim, Germany, pp. 199-231.
19. Huls, G. A., I. A. Heijnen, M. E. Cuomo, J. C. Koningsberger, I. Wiegman, E. Boel, A. R. van der Vuurst de Vries, S. A. Loyson, W. Helfrich, G. P. Berge Henegouwen, et al. 1999. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat. Biotechnol. 17: 276-281.
20. Lindmo, T., E. Boven, F. Cuttita, J. Fedorko, and P. A. Bunn, Jr. 1984. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 172: 77-89.
21. Huls, G., D. Gestel, J. van der Linden, E. Moret, and T. Logtenberg. 2001. Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies. Cancer Immunol. Immunother. 50: 163-171.
22. Naundorf, S., S. Preithner, P. Mayer, S. Lippold, A. Wolf, F. Hanakam, I. Fichtner, P. Kufer, T. Raum, G. Riethmuller, et al. 2002. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int. J. Cancer 100: 101-110.
23. Buchsbaum, D. J., P. G. Brubaker, D. E. Hanna, A. A. Glatfelter, V. H. Terry, D. M. Guilbault, and Z. Steplewski. 1990. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies. Cancer Res. 50(3 Suppl.): 993s-999s.
24. Velders, M. P., S. V. Litvinov, S. O. Warnaar, A. Gorter, G. J. Fleuren, V. R. Zurawski, Jr., and L. R. Coney. 1994. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. 54: 1753-1759.
25. Rojas, R., and G. Apodaca. 2002. Immunoglobulin transport across polarized epithelial cells. Nat. Rev. Mol. Cell Biol. 2: 1-12.
26. Borvak, J., J. Richardson, C. Medesan, F. Antohe, C. Radu, M. Simionescu, V. Ghetie, and E. S. Ward. 1980. Functional expression of the MHC class I-related receptor, FcRn in endothelial cells of mice. Int. Immunol. 10: 1289-1298.
27. Junghans, R. P. 1997. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. 16: 29-57.
28. Ober, R. J., C. G. Radu, V. Ghetie, and E. S. Ward. 2001. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13: 1551-1559.
29. Ward, E. S., J. Zhou, V. Ghetie, and R. J. Ober. 2003. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol. 15: 187-195.
30. Kroesen, B.-J., R. A. Jansen, J. Buter, J. Nieken, D. T. Sleijfer, N. H. Mulder, and L. F. de Leij. 1995. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiology aspects. J. Hematother. 4: 409-414.
31. Roovers, R. C., P. Henderikx, W. Helfrich, E. van der Linden, A. Reurs, A. P. de Bruine, J. Arends, L. F. de Leij, and H. R. Hoogenboom. 1998. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br. J. Cancer 78: 1407-1416.